Green-Lipped Mussel
Evidence Fact Sheet
Perna canaliculus
Green-lipped mussel (Perna canaliculus) is a New Zealand shellfish whose standardized lipid extract (Lyprinol/PCSO-524) and freeze-dried powder are studied for joint comfort, exercise recovery and airway inflammation via COX/5-LOX and NF-kB modulation. Evidence is mixed, with honest RCT negatives. Contains shellfish.
Also known as: Greenshell mussel · Perna canaliculus · New Zealand green-lipped mussel · GLM · Lyprinol® / PCSO-524 (standardized lipid extract)
Overview
Green-lipped mussel (Perna canaliculus), also called New Zealand greenshell mussel or GLM, is a marine shellfish supplied either as a freeze-dried whole-mussel powder or as a standardized supercritical-CO2 lipid extract (Lyprinol / PCSO-524). Its researched mechanisms center on marine omega-3 and furan fatty acids that competitively inhibit COX-2 and 5-LOX, lowering leukotriene synthesis, plus downregulation of NF-kB signaling and a glycosaminoglycan content proposed as a cartilage-matrix substrate. It is most studied for joint comfort/mobility in osteoarthritis research, with smaller bodies of work in post-exercise muscle recovery and airway inflammation. Typical research doses are 150-300 mg/day of the standardized lipid extract over 8-12 weeks, or roughly 1000-3000 mg/day of freeze-dried whole-mussel powder; the extract and the powder are not interchangeable on a milligram basis. Regulatory status: a dietary supplement under DSHEA in the US (structure/function claims only, mandatory "Contains Shellfish" allergen labeling), a lawful food supplement in the EU with ZERO EFSA-authorized health claims, and not on the ANVISA positive list in Brazil.
Mechanism of Action
COX-2 inhibition by ETA (eicosatetraenoic acid) + furan fatty acids (research context) · 5-LOX competitive substrate inhibition by ETA, reducing leukotriene (LTB4/LTC4) synthesis · NF-κB nuclear translocation downregulation with reduced TNF-α / IL-1β / IL-6 in research models · Glycosaminoglycan (GAG) content providing cartilage-matrix structural substrate · Marine Omega-3 lipid + trace-element antioxidant (ROS scavenging) activity
Body systems: Musculoskeletal · Immune System · Respiratory & Mucosal Barrier · Cardiovascular · Digestive & Gut · Skin & Connective Tissue
Evidence-Based Benefits
Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Green-Lipped Mussel is not characterized as a treatment for any disease.
Osteoarthritis Joint Pain (Pooled Meta-Analysis)
Meta-analysis supported- -0.46VAS pain effect size
- 95% CI -0.82 to -0.10p = 0.01
- 5 studiesin meta-analysis (9 trials reviewed)
In a systematic review and meta-analysis of greenshell mussel extracts for osteoarthritis, the pooled analysis of five studies found a statistically significant reduction in visual analogue scale (VAS) pain, with the authors describing the effect as moderate and clinically meaningful. This is the strongest single pooled signal for joint comfort, though the review flagged limited evidence quality and called for larger trials.
Reported effect: Pooled VAS pain effect size -0.46 (95% CI -0.82 to -0.10; p = 0.01); five studies pooled from nine clinical trials reviewed
“The pooled analysis demonstrated that greenshell mussel extracts produced meaningful reductions in visual analogue scale (VAS) pain scores with an effect size of -0.46 (95% CI -0.82 to -0.10; p = 0.01). "GSM provided moderate and clinically meaningful treatment effects on OA pain."”
Source: PMID 33738701 · Abshirini 2021 · Inflammopharmacology
Osteoarthritis / Arthritis (Earlier Systematic Review — Honest Negative)
Null / no benefit Meta-analysis supported- 2 of 5RCTs showed benefit
- 5 RCTsfreeze-dried mussel powder
An earlier systematic review of controlled trials reached a cautious, largely negative conclusion: only 2 of 5 randomized controlled trials using freeze-dried mussel powder showed benefit, and the authors judged the evidence inconsistent and not compelling for arthritis. This honest negative tempers the more favorable later meta-analysis and reflects real heterogeneity across formulations.
Reported effect: Only 2 of 5 randomized controlled trials of freeze-dried mussel powder showed benefit; conclusion was that evidence is not conclusive
“Only 2 of 5 randomized controlled trials showed benefits. "There is little consistent and compelling evidence, to date, in the therapeutic use of freeze-dried green-lipped mussel powder products for rheumatoid or osteoarthritis treatment."”
Source: PMID 16220229 · Cobb 2006 · Clinical Rheumatology
Hip/Knee Osteoarthritis Pain (Single RCT — Honest Negative on Primary Outcome)
Null / no benefit RCT supported- 80 patientsmoderate-to-severe hip/knee OA
- no significant differenceVAS / WOMAC pain vs placebo
- p = 0.046WOMAC stiffness (secondary)
A double-blind, placebo-controlled RCT of a BioLex green-lipped mussel extract in 80 patients with moderate-to-severe hip/knee osteoarthritis found no significant between-group difference on the primary VAS and WOMAC pain outcomes at 12 weeks; only a secondary WOMAC stiffness measure improved (p = 0.046). The authors concluded the extract did not confer clinical benefit over the intervention period. A prominent honest negative for joint pain.
Reported effect: No significant between-group difference in VAS or WOMAC pain at week 12 (n=80); secondary WOMAC stiffness improved vs placebo (p = 0.046)
“"At week 12, there were no significant differences in VAS or WOMAC pain subscale between active and placebo groups" ... "Joint stiffness (measured by WOMAC-B stiffness) in the GLM group improved compared with placebo (p = 0.046)" ... "BioLex® -GLM extract did not confer clinical benefit in moderate to severe OA over the intervention period"”
Source: PMID 28830491 · Stebbings 2017 · BMC Complement Altern Med
Post-Exercise Muscle Recovery (RCT)
RCT supported- 20 menuntrained, crossover
- p < 0.05peak torque at 48 h / 72 h
In a double-blind, placebo-controlled crossover trial in 20 untrained men, four weeks of Greenshell mussel powder before eccentric exercise significantly improved isometric and concentric peak torque recovery at 48 and 72 hours (p < 0.05) and was associated with lower plasma creatine kinase and reduced soreness. The authors concluded it supports muscle recovery from exercise-induced muscle damage.
Reported effect: Significantly improved (p < 0.05) isometric and concentric peak torque at 48 h and 72 h post-exercise in 20 untrained men
“"Twenty untrained adult men were recruited into a double-blind, placebo-controlled, cross-over study" ... "significantly improving (p < 0.05) isometric and concentric peak torque at 48 h and 72 h post exercise, respectively" ... "This study provides evidence for GSM powder being effective in supporting muscle recovery from EIMD."”
Source: PMID 37242198 · Lomiwes 2023 · Nutrients
Atopic Asthma / Airway Inflammation (RCT)
RCT supported- 46 patientssteroid-naive atopic asthma
- 8 weeksdouble-blind, placebo-controlled
An 8-week double-blind, placebo-controlled trial in 46 patients with steroid-naive atopic asthma reported a significant increase in morning peak expiratory flow, a significant decrease in daytime wheeze, and a significant reduction in exhaled hydrogen peroxide (an airway inflammation marker) with the green-lipped mussel lipid extract versus placebo. The authors framed this as a possible beneficial effect rather than a definitive treatment outcome.
Reported effect: Significant increase in morning PEF, decrease in daytime wheeze, and reduction in exhaled hydrogen peroxide vs placebo in 46 patients over 8 weeks (specific magnitudes not stated in abstract text fetched)
“N = 46 patients with steroid-naïve atopic asthma; two capsules twice daily for 8 weeks. "The authors conclude that lipid extract of New Zealand green-lipped mussel may have some beneficial effect in patients with atopic asthma."”
Source: PMID 12358334 · Emelyanov 2002 · European Respiratory Journal
Dosage (research context · not a recommendation)
Standardized lipid extract (Lyprinol® / PCSO-524) 150-300 mg/day in osteoarthritis research over 8-12 weeks; ~1200 mg/day (≈200 mg lipid fraction) in exercise-recovery research; freeze-dried whole-mussel powder 1000-3000 mg/day delivers an equivalent lipid load at a much higher gross dose. The supercritical-CO₂ lipid extract and the whole-mussel powder are NOT interchangeable on a mg basis. Educational reference, not a dosing recommendation.
Regulatory Status · 4 Markets
- US · FDA
- Dietary supplement under DSHEA; structure/function claims only (joint health/mobility, healthy inflammatory response, post-exercise recovery). NDI notification history for Lyprinol®/PCSO-524 (Pharmalink, up to 300 mg/day lipid extract); whole-mussel powder marketed under pre-1994 Old Dietary Ingredient (ODI) basis. Mandatory 'Contains Shellfish' allergen labeling (FALCPA 2004). FDA disclaimer required on all S/F claims. No 'FDA approved' language permitted.
- EU · EFSA
- Food-supplement ingredient (NOT a Novel Food — pre-1997 EU food-use history). ZERO authorized health claims: EFSA did not establish a cause-effect relationship for joint health / mobility (high RCT heterogeneity). Sold lawfully as a food supplement in UK/DE/NL/FR. Mandatory shellfish-allergen labeling (Reg 1169/2011 Annex II).
- CN · China
- Whole green-lipped mussel / mussel meat & freeze-dried powder are edible as conventional food, zero functional claims permitted; the lipid extract (Lyprinol) is not on the novel-food list and needs registration.
- BR · ANVISA
- Not on the ANVISA dietary-supplement positive list (RDC 243/2018); GLM lipid extract would require the innovative-ingredient pathway (RDC 239/2018, ~12-24 month review). No authorized functional claim. Portuguese 'Contém moluscos' allergen labeling and a local regulatory representative required.
Safety
Generally well tolerated; whole-mussel powder tolerated to 3000 mg/day over 12 weeks. Mild GI upset (nausea, bloating) in under 5% of subjects. HARD allergen rule: contains shellfish — absolutely contraindicated in shellfish-allergic individuals; severe (including fatal) anaphylaxis reported, so "Contains Shellfish" labeling is mandatory in all markets (FDA FALCPA, EU Reg 1169/2011, SAMR GB 7718-2011). Theoretical additive antiplatelet effect with anticoagulants (marine Omega-3); insufficient pregnancy/lactation safety data — consult a physician. Source quality matters: New Zealand MPI-regulated farming keeps heavy metals below FDA/EU limits (request supplier CoA). Educational, not medical advice.
Related
Goals: joint-bone · inflammation-relief
Lifestyles: senior-60-plus
References
PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.
- PMID 33738701 · Abshirini 2021 · Inflammopharmacology — Osteoarthritis Joint Pain (Pooled Meta-Analysis)
- PMID 16220229 · Cobb 2006 · Clinical Rheumatology — Osteoarthritis / Arthritis (Earlier Systematic Review — Honest Negative)
- PMID 28830491 · Stebbings 2017 · BMC Complement Altern Med — Hip/Knee Osteoarthritis Pain (Single RCT — Honest Negative on Primary Outcome)
- PMID 37242198 · Lomiwes 2023 · Nutrients — Post-Exercise Muscle Recovery (RCT)
- PMID 12358334 · Emelyanov 2002 · European Respiratory Journal — Atopic Asthma / Airway Inflammation (RCT)
Frequently Asked Questions
1. What is green-lipped mussel and how is it thought to work?
Green-lipped mussel (Perna canaliculus), also called New Zealand greenshell mussel or GLM, is a marine shellfish sold as a freeze-dried whole-mussel powder or as a standardized lipid extract (Lyprinol / PCSO-524). Its researched mechanisms involve marine omega-3 and furan fatty acids that inhibit the COX-2 and 5-LOX inflammatory enzymes and downregulate NF-kB signaling, plus a glycosaminoglycan content proposed as a cartilage-matrix substrate.
2. Does the evidence show it helps osteoarthritis joint pain?
It is mixed. A 2021 meta-analysis (Abshirini, PMID 33738701) pooled five studies and found a statistically significant VAS pain reduction with an effect size of -0.46 (95% CI -0.82 to -0.10; p = 0.01), describing it as moderate and clinically meaningful. But an earlier systematic review (Cobb 2006, PMID 16220229) found only 2 of 5 RCTs positive and called the evidence not conclusive, and a well-powered RCT (Stebbings 2017, PMID 28830491, n=80) found no significant difference vs placebo on primary pain outcomes. This is why EFSA has authorized zero health claims for it.
3. What is the typical dose used in research?
Studies typically use 150-300 mg/day of the standardized lipid extract (Lyprinol / PCSO-524) over 8-12 weeks, or roughly 1000-3000 mg/day of freeze-dried whole-mussel powder. The lipid extract and the powder are not interchangeable on a milligram basis. This is educational reference information, not a dosing recommendation.
4. Is green-lipped mussel safe? Any major warning?
The biggest hard rule is that it contains shellfish and is absolutely contraindicated in shellfish-allergic individuals, with severe (including fatal) anaphylaxis reported, so 'Contains Shellfish' labeling is mandatory across markets. Otherwise it is generally well tolerated in studies, with mild GI upset in a small minority of subjects. There is a theoretical additive antiplatelet effect with anticoagulants and insufficient pregnancy/lactation safety data. This is educational information, not medical advice.
Last evidence review: 2026-06-13